Genetic testing can guide personalized AMD treatment

Article

During a presentation at SECO, Jeffry Gerson, OD, FAAO, said a simple genetic test gives optometrists the necessary information for developing a personalized care plan for patients with-or at risk for-age-related macular degeneration.

Atlanta, GA-During a presentation at SECO, Jeffry Gerson, OD, FAAO, said a simple genetic test gives optometrists the necessary information for developing a personalized care plan for patients with-or at risk for-age-related macular degeneration.

While other factors, such as age, weight, and whether a patient smokes, nothing can help predict the likelihood of a patient developing AMD over the next 2, 5, and 10 years like a genetic test. The test can also tell the optometrist which types of therapy would be most beneficial to the patient.

“It’s bad to be a smoker, when it comes to AMD.  It’s bad to have bad genetics. It’s really bad to have bad genes and be a smoker,” says Dr. Gerson. He said patients with bad genetics are at a 400xs greater risk for developing AMD than those with good genetics, and adding in smoking or other factors make that risk increases even more.

Dr. Gerson says he uses the Macula Risk test, which requires the patient to swab the inside of her cheek. The test is sent off to a lab and results are ready within 2-3 weeks.

If a patient has a diagnosis of drusen or AMD and has insurance, the test costs the patient about $25, says Dr. Gerson. For patients without insurance, the test costs $500-$700.

In addition to identifying patients who are most at risk for AMD, it can bring peace of mind to those who find they are not at risk for the disease.

“Our role is to be preventative and proactive. I ask myself, ‘If this were my mom, what would I do?’ And wouldn’t it be great to tell someone ‘You don’t have to worry’?” says Dr. Gerson.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
© 2025 MJH Life Sciences

All rights reserved.